Evolocumab - Amgen

Drug Profile

Evolocumab - Amgen

Alternative Names: AMG-145; Repatha

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Amgen Astellas BioPharma; University Hospital Inselspital
  • Class Antihyperlipidaemics; Cardiovascular therapies; Monoclonal antibodies
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypercholesterolaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary disorders; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa; Myocardial infarction; Stroke

Most Recent Events

  • 11 Jul 2018 Launched for Hypercholesterolaemia (Combination therapy, In adolescents, In adults) in India (SC)
  • 11 Jul 2018 Registered for Hypercholesterolaemia (Combination therapy, In adults, In adolescents) in India (SC), prior to July 2018
  • 27 Jun 2018 Amgen plans the HUYGENS phase III trial for Coronary Artery Disease in October 2018 , (NCT03570697)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top